7012-88-6

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
7-CHLORO-2-METHYL-1H-QUINAZOLIN-4-ONE is used as a research compound for its potential antitumor, antiviral, and antifungal properties. Its medicinal properties make it a promising candidate for the development of new pharmaceutical drugs.
Used in Antitumor Applications:
In the field of oncology, 7-CHLORO-2-METHYL-1H-QUINAZOLIN-4-ONE is used as a potential therapeutic agent for various types of cancer. Its antitumor properties are being studied to explore its efficacy in treating different malignancies.
Used in Antiviral Applications:
7-CHLORO-2-METHYL-1H-QUINAZOLIN-4-ONE is used as a potential antiviral agent, with its properties being investigated for the treatment of various viral infections.
Used in Antifungal Applications:
In the field of mycology, 7-CHLORO-2-METHYL-1H-QUINAZOLIN-4-ONE is used as a potential antifungal agent, being studied for its effectiveness against various fungal infections.
Used as an Enzyme Inhibitor:
7-CHLORO-2-METHYL-1H-QUINAZOLIN-4-ONE is also used as a potential inhibitor of certain enzymes, which can be beneficial in the treatment of specific medical conditions.
Used in Therapeutic Agent Development:
7-CHLORO-2-METHYL-1H-QUINAZOLIN-4-ONE is used in the development of therapeutic agents for various medical conditions, leveraging its potential pharmacological activities to improve patient outcomes.

InChI:InChI=1/C9H7ClN2O/c1-5-11-8-4-6(10)2-3-7(8)9(13)12-5/h2-4H,1H3,(H,11,12,13)

Upstream product

• 708-73-6 7-chloro-2-methyl-4H-3,1-benzoxazin-4-one 
• 13421-13-1 4-chloro-2-iodobenzoic acid 
• 124-42-5 acetamidine hydrochloride 
• 64-17-5 ethanol 
• 38487-86-4 2-amino-4-chlorobenzonitrile 
• 1397833-65-6 (2-amino-4-chlorophenyl) (benzotriazole-1-yl)methanone 
• 78-39-7 Triethyl orthoacetate 
• 5900-59-4 2-amino-4-chlorobenzamide 
• 5900-56-1 2-acetylamino-4-chlorobenzoic acid 
• 75-05-8 acetonitrile 
• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 108-24-7 acetic anhydride 
• 7033-57-0 2-Acetylamino-4-chlor-benzoesaeure-amid 
• 942319-20-2 4-chloro-2-iodobenzamide 

Downstream Products

• 38154-43-7 4,7-dichloro-2-methyl-3,4-dihydroquinazoline 
• 1258327-25-1 7-chloro-4-[2-(diphenylphosphanyl)naphthalen-1-yl]-2-methylquinazoline 
• 340735-27-5 {7-Chloro-2-[(E)-2-(3-nitro-phenyl)-vinyl]-quinazolin-4-ylamino}-acetic acid 
• 340734-98-7 7-chloro-2-[2-(3-nitrophenyl)vinyl]quinazolin-4(3H)-one 

Relevant academic research and scientific papers

Cobalt-Catalyzed Tandem Transformation of 2-Aminobenzonitriles to Quinazolinones Using Hydration and Dehydrogenative Coupling Strategy

A tandem synthesis of quinazolinones from 2-aminobenzonitriles is demonstrated here by using an aliphatic alcohol-water system. For this transformation, a cheap and easily available cobalt salt and P(CH2CH2PPh2)3 (PP3) ligand were employed. The substrate scope, scalability, and synthesis of natural products exhibited the vitality of this protocol.

Visible-light induced copper(i)-catalyzed oxidative cyclization of: O -aminobenzamides with methanol and ethanol via HAT

The use of the in situ generated ligand-copper superoxo complex absorbing light energy to activate the alpha C(sp3)-H of MeOH and EtOH via the hydrogen atom transfer (HAT) process for the synthesis of quinazolinones by oxidative cyclization of alcohols with o-aminobenzamide has been investigated. The synthetic utility of this protocol offers an efficient synthesis of a quinazolinone intermediate for erlotinb (anti-cancer agent) and 30 examples were reported.

Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases

Aberrant activation of FMS-like tyrosine receptor kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid leukemia (AML) in 20–30% of patients. In this study we identified a highly selective (phenylethenyl)quinazoline compound family as novel potent inhibitors of the FLT3-ITD and FLT3-D835Y kinases. Their prominent effects were confirmed by biochemical and cellular proliferation assays followed by mice xenograft studies. Our modelling experiments and the chemical structures of the compounds predict the possibility of covalent inhibition. The most effective compounds triggered apoptosis in FLT3-ITD AML cells but had either weak or no effect in FLT3-independent leukemic and non-leukemic cell lines. Our results strongly suggest that our compounds may become therapeutics in relapsing and refractory AML disease harboring various ITD and tyrosine kinase domain mutations, by their ability to overcome drug resistance.

One-pot synthesis of quinazolin-4(3H)-ones and 2,3-dihydroquinazolin-4(1H)-ones utilizing N-(2-aminobenzoyl)benzotriazoles

A convenient and efficient method has emerged for the one-pot synthesis of substituted quinazolin-4(3H)ones and nonaromatic alkaloids. 2-Substituted quinazolin-4(3H)-ones, 2,3-disubstituted quinazolin-4(3H)-ones, and 2,3-dihydroquinazolin-4(1H)-ones were obtained at yields of 46% to 95% by a one-pot reaction of N-(2-aminobenzoyl) benzotriazoles with amines and orthoesters or aldehydes under catalyst-free conditions.

Quinazolin-4(3H)-ones and 5,6-dihydropyrimidin-4(3H)-ones from β-aminoamides and orthoesters

Quinazolin-4(3H)-ones have been prepared in one step from 2-aminobenzamides and orthoesters in the presence of acetic acid. Simple 2-aminobenzamides were easily converted to the heterocycles by refluxing in absolute ethanol with 1.5 equivalents of the orthoester and 2 equivalents of acetic acid for 12–24 h. Ring-substituted and hindered 2-aminobenzamides as well as cases incorporating an additional basic nitrogen required pressure tube conditions with 3 equivalents each of the orthoester and acetic acid in ethanol at 110?C for 12–72 h. The reaction was tolerant towards functionality on the benzamide and a range of structures was accessible. Workup involved removal of the solvent under vacuum and either recrystallization from ethanol or trituration with ether-pentane. Several 5,6-dihydropyrimidin-4(3H)-ones were also prepared from 3-amino-2,2-dimethylpropionamide. All products were characterized by melting point, FT-IR, 1H-NMR, 13C-NMR, and HRMS.

Metal-free oxidative cyclization of 2-amino-benzamides, 2-aminobenzenesulfonamide or 2-(aminomethyl)anilines with primary alcohols for the synthesis of quinazolinones and their analogues

A general metal-free oxidative cyclization process has been developed for the synthesis of quinazolinones, benzothiadiazines and quinazolines. By this protocol, a range of substituted 2-aminobenzamides, 2-aminobenzenesulfonamide and 2-(aminomethyl)anilines react with various alcohols, leading to the desired annulated products smoothly. This protocol features many advantages as broad substrate scope, mild reaction conditions, low environmental pollution, high atom-economy and good to excellent yields.

Structure-Based Target-Specific Screening Leads to Small-Molecule CaMKII Inhibitors

Target-specific scoring methods are more commonly used to identify small-molecule inhibitors among compounds docked to a target of interest. Top candidates that emerge from these methods have rarely been tested for activity and specificity across a family

A copper-catalyzed Ritter-type cascade via iminoketene for the synthesis of quinazolin-4(3H)-ones and diazocines

We have developed a copper-catalyzed Ritter-type reaction/cyclization cascade of anthranilic acids and nitriles, affording the quinazolin-4(3H)-ones. The cascade proceeds through a Ritter-type reaction capturing the iminoketene intermediates by nitriles. Furthermore, we found a novel Ritter-type reaction/condensation/intramolecular anti-Markovnikov hydroamination cascade, providing access to functionalized diazocines in one-pot.

HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS

The invention relates to heterocyclic compounds and their use as antibiotics and/or as antibiotic potentiators. The compounds may act as colistin potentiators and SOS inhibitors.

STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS

The present invention relates to styryl quinazoline derivatives of the general formula (I) and pharmaceutically acceptable solvates, hydrates, salts, regioisomeric and polymorphic forms thereof as well as pharmaceutical compositions containing at least on